

Identity: Mr.

Title: Professor of Cardiology, FESC

Family Name(s): Atar

First Name(s): Dan

Age: 65

Application for the following position in the HFA Board or Nominating Committee:  
Ordinary Board member

Photo:



### Place of work

*If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.*

Institute/organisation:	Oslo University Hospital Ulleval
Department:	Dept. Of Cardiology
Address:	Kirkeveien 166
Post code / Zip:	0450 Oslo
Country:	Norway

### General Curriculum Vitae (500 words max)

*Please also include your H index and top 5 to 10 publications in the last 5 years*

Professor Dan Atar is Head of Research and Professor of Cardiology at the Oslo University Hospital in Norway. He graduated from Basel University, trained in internal medicine and cardiology in Switzerland, Denmark, and the US, and held a Post-doc position at the Johns Hopkins University in Baltimore (1991-94) and at the Universities of Copenhagen and Zurich, where he worked as a senior cardiologist. In 2002, he received a full professorship in cardiology at the University of Oslo and was appointed Head of Cardiology Dept. at the Aker University Hospital in Oslo, and since 2010 the Oslo University Hospital. He holds a Visiting Associate Professorship at the Johns Hopkins University in Baltimore, USA.

Professor Atar has written over 560 articles and book chapters (H-index 82) and holds the fellowship-titles FESC, FACC, FEHRA and inaugural FAHA. He served as Chairman of the ESC Working Group on Cardiovascular Pharmacotherapy. He was chairing an EU-FP7 research consortium (Mitocare) to study reperfusion injury in STEMI. He was on several ESC guideline writing committees, amongst others the 2008 ESC Heart Failure Guidelines, the 2010, 2012 and 2016 ESC Guidelines on Atrial Fibrillation as well as the 2012 STEMI-guideline and the 2018 Universal Definition of AMI Guideline. In 2012 Professor Atar was elected as Councillor and Board member of the ESC, in 2014 as Vice President of the ESC, and in 2018 as Treasurer of the ESC. For his scientific achievements, he earned a doctor honoris causa in 2015 and since 2016 he appears on the prestigious Clarivate list of "the most cited researchers of the world". In 2023, he was bestowed with the 'Lifetime Achievement Award in Heart Research' by H.M. the King of Norway.

#### A few publications:

**Atar D**, Auricchio A, Blomström-Lundqvist C.: Cardiac device infection: removing barriers to timely and adequate treatment. Eur Heart J. 2023 Sep 14;44(35):3323-3326

Kotecha D, Asselbergs FW, Achenbach S, Anker SD, **Atar D**, Baigent C, Banerjee A, Beger B, Brobert G, Casadei B, Ceccarelli C, Cowie MR, Crea F, Cronin M, Denaxas S, Derix A, Fitzsimons D, Fredriksson M, Gale CP, Gkoutos GV, Goettsch W, Hemingway H, Ingvar M, Jonas A, Kazmierski R, Løgstrup S, Thomas Lumbers R, Lüscher TF, McGreavy P, Piña IL, Roessig L, Steinbeisser C, Sundgren M, Tyl B, van Thiel G, van Bochove K, Vardas PE, Villanueva T, Vrana M,

Weber W, Weidinger F, Windecker S, Wood A, Grobbee DE; Innovative Medicines Initiative BigData@Heart Consortium, European Society of Cardiology, CODE-EHR international consensus group.: CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research. Eur Heart J. 2022 Oct 7;43(37):3578-3588

Butt JH, Dewan P, Jhund PS, Anand IS, **Atar D**, Ge J, Desai AS, Echeverria LE, Køber L, Lam CSP, Maggioni AP, Martinez F, Packer M, Rouleau JL, Sim D, Van Veldhuisen DJ, Vrtovc B, Zannad F, Zile MR, Gong J, Lefkowitz MP, Rizkala AR, Solomon SD, McMurray JJV.: Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2022 Sep 20;80(12):1130-1143

Saldarriaga C, **Atar D**, Stebbins A, Lewis BS, Abidin IZ, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, O'Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group.: Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. Eur J Heart Fail. 2022 May;24(5):782-790

**Atar D**, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, CerezoOlmos C, Underberg J, Keech A, Tokgözoğlu L, Bonaca MP: New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. 2020 Dec 18;319:51-61.

**Atar D**, Berge E, Le Heuzey JY, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Kakkar AK; GARFIELD-AF Investigators. The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. Europace. 2020;22, 195–204.

Fox KAA, Metra M, Morais J, **Atar D**: The myth of 'stable' coronary artery disease. Nat Rev Cardiol. 2020 Jan;17(1):9-21.

**Atar D**, Grundvold I.: On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient? Eur Heart J. 2019;40;19,1501–1503.

Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernæs KH, Vethe NT, Prescott E, Jensen SE, Rødevand O, Jortveit J, Bendz B, Schirmer H, Køber L, Bøtker HE, Larsen AI, Vikenes K, Steigen T, Wiseth R, Pedersen T, Edvardsen T, Otterstad JE, **Atar D**. : BETAblocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J. 2019 Feb;208:37-46.

### **Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society**

*150 words maximum*

Since my post-doc fellowship at The Johns Hopkins University, I have been studying various aspects of myocardial function in the broader context of Heart Failure. I am proud to have served on one of the ESC Heart Failure Guidelines (the one published in 2008). Ever since, I have been a participant (and often also a faculty member) of the annual HFA congresses.

### **Why are you motivated to join the HFA Board or Nominating Committee?**

*150 words maximum*

Firstly, HF is in the middle of my clinical and scientific interest. Second, I am willing to serve the HF community in an active role within this excellent association under the ESC.

### **How will you combine your HFA position with your daily clinical/research workload?**

*80 words maximum*

My current academic and clinical position allows me sufficient leeway to serve the HFA with a substantial part of my combined workload. It will be a pleasure and inspiration to serve the HFA.